Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19

Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.

Automated summary

Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. Nucleocapsid antigenemia can serve as a marker for persistent infection and therapeutic response in these patients, especially those treated with anti-CD20 immunotherapy.